FACTBOX-Moderna's mRNA coronavirus vaccine

    * For a separate FACTBOX on other vaccines, click, and click for

    Nov 16 (Reuters) - Moderna Inc became the second U.S company to release data from a
large study of its experimental vaccine, saying it was 94.5% effective against COVID-19.
    It will seek emergency use authorization from the U.S. Food and Drug Administration once it
has more safety data, expected later this month.
    Its first analysis was based on 95 cases of COVID-19, 90 of which received a placebo with 5
receiving the vaccine. There were 11 severe cases in the placebo group and none among those that
got the vaccine.
    The 95 cases included 15 adults aged 65 or over, and 20 participants from diverse
communities including 12 people who identified as Hispanic, 4 Black Americans, 3 Asian Americans
and 1 person who was multiracial.
    The results come one week after Pfizer Inc and German partner BioNTech SE
said their experimental vaccine was more than 90% effective based on initial data.
    Moderna, which went public in 2018, has received nearly $1 billion in research and
development funding from the U.S. government and has a deal worth $1.5 billion to supply 100
million doses. The U.S. government has an option for another 400 million doses and Moderna also
has supply deals with other countries. 
    Below are more details on Moderna's vaccine: 
    - The experimental vaccine, called mRNA-1273, is based on messenger RNA (mRNA) technology,
which relies on synthetic genes that can be generated and manufactured in weeks, and produced at
scale more rapidly than conventional vaccines. Pfizer's vaccine also uses mRNA technology.
    - Other firms developing COVID-19 vaccines that use mRNA technology include Germany's
Curevac and U.S. biotech firm Arcturus Therapeutics Holdings Inc.
    - An authorized, safe and effective mRNA vaccine for COVID-19 would be a first for the
technology, which has previously not been used for an approved vaccine or drug.
    - The United Kingdom's health regulator started a real-time review of its experimental
COVID-19 vaccine in October. The European Medicines Agency, Canada and Switzerland have also
begun rolling reviews.
    - Moderna expects to be able to produce 20 million doses by the end of the year, and between
500 million and 1 billion in 2021. 
    - The company was among the first to conduct COVID-19 vaccine human trials, starting in
March and its late-stage 30,000 participant testing began on July 27 in the United States. It
finished enrolling participants in October.
    - The company slowed enrollment in September to increase the diversity of the trial
population. It ultimately enrolled 3,000 Black American participants and more than 6,000
participants who are Hispanic.
    - The vaccine candidate is being tested at about 89 clinical research sites in the United
    - Moderna's U.S. trial was the first under the government's Operation Warp Speed program and
is funded by Biomedical Advanced Research and Development Authority and National Institute of
Allergy and Infectious Diseases, part of the National Institutes of Health.
(most recent first)          
 U.S.          100 mln + option     $1.53 bln       Unspecified                          
               for 400 mln more                                              
 EU            80 mln               In talks        Unspecified                          
 Canada        Unspecified          Unspecified     Unspecified                          
 Japan         50 mln doses, to be  Unspecified     H1 of 2021                           
               distributed by                                                
 Israel        Unspecified          Unspecified     Unspecified                          
 Qatar         Unspecified          Unspecified     As soon as vaccine is                
                                                    approved and released    
(Source: Reuters reporting, press releases, clinical trial registers)    

 (Reporting by Manas Mishra, Vishwadha Chander and Mrinalika Roy in Bengaluru; Editing by
Caroline Humer and Edwina Gibbs)